Esophageal Cancer Clinical Trial

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Life expectancy at least 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
Tumor Specimen availability

Exclusion Criteria:

Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
Active hepatitis B or C or tuberculosis
Positive test for human immunodeficiency virus (HIV) infection
Acute or chronic active Epstein-Barr virus (EBV) infection at screening
Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Active or history of autoimmune disease
Prior allogeneic stem cell or organ transplantation

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

395

Study ID:

NCT05581004

Recruitment Status:

Recruiting

Sponsor:

Genentech, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 33 Locations for this study

See Locations Near You

Stanford University'
San Francisco California, 94305, United States
University Of Colorado
Aurora Colorado, 80045, United States
Florida Cancer Specialists - Sarasota
Sarasota Florida, 34232, United States
Winship Cancer Institute
Atlanta Georgia, 30322, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Henry Ford Hospital
Detroit Michigan, 48202, United States
Washington University Medical Center, Division of Oncology
Saint Louis Missouri, 63110, United States
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08901, United States
The West Clinic - Memphis (Union Ave)
Germantown Tennessee, 38138, United States
SCRI Oncology Partners
Nashville Tennessee, 37203, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio Texas, 98229, United States
Kinghorn Cancer Centre; St Vincents Hospital
Darlinghurst New South Wales, 2010, Australia
Monash Health Monash Medical Centre
Clayton Victoria, 3168, Australia
Linear Clinical Research Ltd
Nedlands Western Australia, 6009, Australia
UZ Antwerpen
Edegem , 2650, Belgium
CHU de Liège
Liège , 4000, Belgium
GasthuisZusters Antwerpen
Wilrijk , 2610, Belgium
British Columbia Cancer Agency
Vancouver British Columbia, V5Z 4, Canada
Ottawa Hospital Regional Cancer Centre
Ottawa Ontario, K1H 8, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 1, Canada
Sir Mortimer B Davis Jewish General Hospital
Montreal Quebec, H3T 1, Canada
Seoul National University Hospital
Seoul , 03080, Korea, Republic of
Asan Medical Center - PPDS
Seoul , 05505, Korea, Republic of
Samsung Medical Center - PPDS
Seoul , 06351, Korea, Republic of
Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy
Seoul , 120-7, Korea, Republic of
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam , 1066 , Netherlands
Universitair Medisch Centrum Groningen
Groningen , 9713 , Netherlands
ICO l?Hospitalet ? Hospital Duran i Reynals
L?Hospitalet De Llobregat Barcelona, 08908, Spain
Hospital Universitario Vall d'Hebron - PPDS
Barcelona , 08035, Spain
START MADRID_Hospital Universiario Fundacion Jimenez Diaz
Madrid , 28040, Spain
Hospital Universitario 12 De Octubre
Madrid , 28041, Spain
Hospital Universitario Virgen de la Victoria
Malaga , 29010, Spain
Hospital Clinico Universitario de Valencia
Valencia , 46010, Spain

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

395

Study ID:

NCT05581004

Recruitment Status:

Recruiting

Sponsor:


Genentech, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider